These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. Boyanovsky BB; van der Westhuyzen DR; Webb NR J Biol Chem; 2005 Sep; 280(38):32746-52. PubMed ID: 16040605 [TBL] [Abstract][Full Text] [Related]
12. Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice. Wen Y; Ahmad F; Mohri Z; Weinberg PD; Leake DS Atherosclerosis; 2019 Dec; 291():9-18. PubMed ID: 31629988 [TBL] [Abstract][Full Text] [Related]
14. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Torzewski M; Suriyaphol P; Paprotka K; Spath L; Ochsenhirt V; Schmitt A; Han SR; Husmann M; Gerl VB; Bhakdi S; Lackner KJ Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2130-6. PubMed ID: 15345515 [TBL] [Abstract][Full Text] [Related]
15. The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection. Torzewski M Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768918 [TBL] [Abstract][Full Text] [Related]